Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer

J Mol Model. 2022 Mar 24;28(4):100. doi: 10.1007/s00894-022-05081-3.

Abstract

Vascular endothelial growth factor (VEGF) and its receptor play an important role both in physiologic and pathologic angiogenesis, which is identified in ovarian cancer progression and metastasis development. The aim of the present investigation is to identify a potential vascular endothelial growth factor inhibitor which is playing a crucial role in stimulating the immunosuppressive microenvironment in tumor cells of the ovary and to examine the effectiveness of the identified inhibitor for the treatment of ovarian cancer using various in silico approaches. Twelve established VEGF inhibitors were collected from various literatures. The compound AEE788 displays great affinity towards the target protein as a result of docking study. AEE788 was further used for structure-based virtual screening in order to obtain a more structurally similar compound with high affinity. Among the 80 virtual screened compounds, CID 88265020 explicates much better affinity than the established compound AEE788. Based on molecular dynamics simulation, pharmacophore and comparative toxicity analysis of both the best established compound and the best virtual screened compound displayed a trivial variation in associated properties. The virtual screened compound CID 88265020 has a high affinity with the lowest re-rank score and holds a huge potential to inhibit the VGFR and can be implemented for prospective future investigations in ovarian cancer.

Keywords: ADMET studies; Egg plot; Molecular docking; Molecular dynamics; Ovarian cancer; VEGF; VEGF inhibitors; Virtual screening.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Female
  • Humans
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Ovarian Neoplasms* / drug therapy
  • Tumor Microenvironment
  • Vascular Endothelial Growth Factor A* / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A